Loading
A phase 2 trial of L19TNF in glioma & glioblastoma, run by Philogen S.p.A., active and no longer recruiting.
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence is a phase 2 interventional study registered as NCT06336291 by Philogen S.p.A., with 90 participants enrolled, started 2024-05-22 and due to reach its primary completion in 2026-06. Interventions recorded: L19TNF and Lomustine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Philogen S.p.A., Glioma & glioblastoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/